Clinical Trials Arena1h
Innovent Biologics doses first subject in trial of ovarian cancer therapy
Innovent Biologics has dosed the first subject in the Phase III HeriCare-Ovarian01 trial of IBI354 for treating PROC with ...
Tharimmune Inc.: Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, toda ...
Innovent Biologics: Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...